USA), discussed institutional results concerning the safety and efficacy of anti-PD-1 checkpoint inhibitors in patients with B cell malignancies who have received prior anti-CD19 CAR T therapy
FOR IMMEDIATE RELEASE February 22, 2017 From the Society for Immunotherapy of Cancer In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients
Quick-reference tables summarizing pivotal trial data for approved immunotherapy agents for GI cancer. Add a tag
Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for hematologic malignancies
09-11-2024 | 13:00 - 17:00 ET
Recombinant IL-2, IL-12, and IL-15 superagonist tagged with a naturally phosphorylated peptide motif (called alum-binding protein (ABP)) were robustly and consistently phosphorylated when purified from Fam20C kinase-expressing HEK293-F cells. ABP-tagged cytokines remained absorbed on alum for more than 2 weeks in vitro in the presence of mouse serum and largely retained functional bioactivity
“T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis” by Daria Briukhovetska et al Immunity (2023) IL-22-producing helper (T h ) cells are associated with poor prognosis in breast and lung cancer
One Year • $100,000 Award This fellowship award will help support the development of the next generation of immunotherapy experts who have a vested interest in furthering the research and translation of cancer immunotherapy. Eligibility Criteria Current SITC member Hold an MD or...
Take a selfie or group photo and tag SITC on social media to help us spread the word about cancer immunotherapy research
“T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy” by Ghilardi et al Nat Med (2024) Abstract: We report a T-cell lymphoma (TCL) occurring three months after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy for non-Hodgkin B-cell lymphoma
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us